All lobbying filings

DLA PIPER LLP (US)

DLA PIPER LLP (US) filed a Q4 report for REGENXBIO INC. on January 16, 2026, reporting $40,000 in lobbying income.

Lobbying for REGENXBIO INC. · Biopharmaceutical company

All filings by DLA PIPER LLP (US) · Everything REGENXBIO INC. has reported

Filing · LD-2 quarterly report Q4 report

Reporting period

4th Quarter 2025

Oct 1 - Dec 31 · Posted Jan 16, 2026

Income

$40,000

What the client paid this registrant for the period.

Client based in

Maryland

Official filing document

Government bodies contacted 2

HOUSE OF REPRESENTATIVES
SENATE

The chambers, agencies and offices the filer named. It does not say who inside them was contacted, or when. Each name opens every filing that named the same body.

Lobbying activity 2

Health Issues

Issues related to rare disease.

Medical/Disease Research/Clinical Labs

Issues related to rare disease.

Source: federal Lobbying Disclosure Act filing, reproduced as filed. Bills are parsed from the activity descriptions.